Welcome to the latest edition of European Respiratory & Pulmonary Diseases, which features a wide range of topical reviews and editorials.
This issue begins with a discussion by Griesenbach and Alton of gene therapy in cystic fibrosis, a subject that has recently experienced a resurgence in interest within the medical community. Pulmonary arterial hypertension (PAH) has also been the focus of considerable recent research, including the regulatory approval of 10 PAH-specific drugs in the last decade. Following this impressive progress, Vachiery presents revisions to European guidelines for the management of PAH. Obstructive sleep apnoea is a common and well-documented condition, but unanswered question remain. Ersu describes the treatment options for children with obstructive sleep apnoea, with a focus on individualised approaches. By contrast, nontuberculous mycobacterial pulmonary disease (NTM-PD) remains poorly understood, despite the fact that it is increasing in prevalence. A review by Loebinger and Welte discusses the unmet needs and latest advances in the diagnosis and treatment of NTM-PD. Finally, Mlika presents a case report of a sarcomatoid carcinoma of the lung that mimicked a thromboembolic disease, highlighting the importance of considering the possibility of lung carcinoma in patients with radiological features related to thromboembolic disease.
European Respiratory & Pulmonary Diseases would like to thank all expert authors who contributed towards this edition. A special thanks goes to our Editorial Board for their continuing support and guidance. We hope that you will find something of interest among these timely and insightful articles.
